Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program

Authors: Quaglino P, Ascierto PA, Consoli F, Queirolo P, Spagnolo F, Morelli MF, Berardi R, Chiarion-Sileni V, Tucci M, Troiani T, Melotti B, Rossi E, Mandala M, Rinaldi G, Marcon IG, Pizzuti M, Del Vecchio M

Source: Cancer Management and Research, Vol Volume 15, Pp 1271-1281 (2023)

Subject Terms: braf mutation, dabrafenib, melanoma, real-world, trametinib, managed access program, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.dovepress.com/characteristics-of-real-world-patients-with-high-risk-brafv600ek-mutat-peer-reviewed-fulltext-article-CMAR; https://doaj.org/toc/1179-1322

Access URL: https://doaj.org/article/61e573f959ce4c9193d56a436410e730

Improved Auto-Marking Confidence for Spoken Language Assessment

Authors: Del Vecchio, M., Malinin, A., Gales, M. J. F.

Source: 2018 IEEE Spoken Language Technology Workshop (SLT) Spoken Language Technology Workshop (SLT), 2018 IEEE. :957-963 Dec, 2018

Relation: 2018 IEEE Spoken Language Technology Workshop (SLT)

Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology

Authors: Queirolo, P. ¹, Cinquini, M. ², Argenziano, G. ³, Bassetto, F. ⁴, Bossi, P. ⁵, Boutros, A. ⁶, Clemente, C. ⁷, de Giorgi, V. ^{8, 9}, Del Vecchio, M. ¹⁰, Patuzzo, R. ¹¹, Pennachioli, E. ¹, Peris, K. ^{12, 13}, Quaglino, P. ¹⁴, Reali, A. ¹⁵, Zalaudek, I. ¹⁶, Spagnolo, F. ^{17, 18, ∗}

Source: In ESMO Open May 2024 9(5)

Is Pokémon GO Watching You? A Survey on the Privacy-Awareness of Location-Based Apps’ Users

Authors: Braghin, C., Del Vecchio, M.

Source: 2017 IEEE 41st Annual Computer Software and Applications Conference (COMPSAC) COMPSAC Computer Software and Applications Conference (COMPSAC), 2017 IEEE 41st Annual. 2:164-169 Jul, 2017

Relation: 2017 IEEE 41st Annual Computer Software and Applications Conference (COMPSAC)

Guidelines for the diagnosis and treatment of basal cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology

Authors: Queirolo, P., Cinquini, M., Argenziano, G., Bassetto, F., Bossi, P., Boutros, A., Clemente, C., de Giorgi, V., Del Vecchio, M., Patuzzo, R., Peris, K., Quaglino, P., Reali, A., Zalaudek, I., Spagnolo, F.

Source: In ESMO Open December 2023 8(6)

Simultaneous stereo-EEG and high-density scalp EEG recordings to study the effects of intracerebral stimulation parameters

Authors: Parmigiani, S., Mikulan, E., Russo, S., Sarasso, S., Zauli, F.M., Rubino, A., Cattani, A., Fecchio, M., Giampiccolo, D., Lanzone, J., D'Orio, P., Del Vecchio, M., Avanzini, P., Nobili, L., Sartori, I., Massimini, M., Pigorini, A.

Source: In Brain Stimulation May-June 2022 15(3):664-675

Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study

Authors: Guida, M., Strippoli, S., Maule, M., Quaglino, P., Ramondetta, A., Chiaron Sileni, V., Antonini Cappellini, G., Queirolo, P., Ridolfi, L., Del Vecchio, M., Cocorocchio, E., Di Giacomo, A.M., Festino, L., Merelli, B., Occelli, M., Brugnara, S., Minisini, A., Sava, S., Tommasi, S., De Summa, S.

Source: In ESMO Open April 2021 6(2)

Anticancer innovative therapy: Highlights from the ninth annual meeting

Authors: Volpari, T., De Santis, F., Bracken, A.P., Pupa, S.M., Buschbeck, M., Wegner, A., Di Cosimo, S., Lisanti, MP., Dotti, G., Massaia, M., Pruneri, G., Anichini, A., Fortunato, O., De Braud, F., Del Vecchio, M., Di Nicola, M. ^*

Source: In Cytokine and Growth Factor Reviews February 2020 51:1-9

Designing a Search Mechanism for Debt Collection

Authors: Del Vecchio, M., Shu Jin, Mistretta, A., Rolando, H., Hope Tuck

Source: 2006 IEEE Systems and Information Engineering Design Symposium Systems and Information Engineering Design Symposium, 2006 IEEE. :168-173 Apr, 2006

Relation: 2006 IEEE Systems and Information Engineering Design Symposium

Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting

Authors: De Santis, F., Del Vecchio, M., Castagnoli, L., De Braud, F., Di Cosimo, S., Franceschini, D., Fucà, G., Hiscott, J., Malmberg, K.J., McGranahan, N., Pietrantonio, F., Rivoltini, L., Sangaletti, S., Tagliabue, E., Tripodo, C., Vernieri, C., Zitvogel, L., Pupa, S.M., Di Nicola, M.

Source: In Cytokine and Growth Factor Reviews December 2018 44:1-10

Innovative Therapy, Monoclonal Antibodies and Beyond

Authors: Di Nicola, M., Apetoh, L., Bellone, M., Colombo, M.P., Dotti, G., Ferrone, S., Muscolini, M., Hiscott, J., Anichini, A., Pupa, S.M., Braud, F.de, Del Vecchio, M.

Source: In Cytokine and Growth Factor Reviews December 2017 38:1-9

Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?

Authors: Franceschini, D., Franzese, C., Navarria, P., Ascolese, A.M., De Rose, F., Del Vecchio, M., Santoro, A., Scorsetti, M.

Source: In Cancer Treatment Reviews November 2016 50:1-8

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma

Authors: Hersh, E.M. ^*, Del Vecchio, M., Brown, M.P., Kefford, R., Loquai, C., Testori, A., Bhatia, S., Gutzmer, R., Conry, R., Haydon, A., Robert, C., Ernst, S., Homsi, J., Grob, J.J., Kendra, K., Agarwala, S.S., Li, M., Clawson, A., Brachmann, C., Karnoub, M., Elias, I., Renschler, M.F., Hauschild, A.

Source: In Annals of Oncology November 2015 26(11):2267-2274

Design of a new experimental facility to reproduce LOVA and LOCA consequences on dust resuspension

Authors: Malizia, A., Gelfusa, M., Francia, G., Boccitto, M., Del Vecchio, M., Di Giovanni, D., Richetta, M., Bellecci, C., Gaudio, P.

Source: In Fusion Engineering and Design October 2015 98-99:2191-2195

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study

Authors: Di Giacomo, A.M., Ascierto, P.A., Queirolo, P., Pilla, L. ^†, Ridolfi, R., Santinami, M., Testori, A., Simeone, E., Guidoboni, M., Maurichi, A., Orgiano, L., Spadola, G., Del Vecchio, M., Danielli, R., Calabrò, L., Annesi, D., Giannarelli, D., Maccalli, C., Fonsatti, E., Parmiani, G. ^{†, ‡}, Maio, M. ^*

Source: In Annals of Oncology April 2015 26(4):798-803

Shadowgraph Technique Applied to STARDUST Facility for Dust Tracking: First Results

Authors: Gaudio, P., Malizia, A., Camplani, M., Barbato, F., Antonelli, L., Gelfusa, M., Del Vecchio, M., Salgado, L., Bellecci, C., Richetta, M.

Source: In Physics Procedia 2015 62:97-101

Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma

Authors: Maio, M. ^*, Danielli, R., Chiarion-Sileni, V., Pigozzo, J., Parmiani, G., Ridolfi, R., De Rosa, F., Del Vecchio, M., Di Guardo, L., Queirolo, P., Picasso, V., Marchetti, P., De Galitiis, F., Mandalà, M., Guida, M., Simeone, E., Ascierto, P.A.

Source: In Annals of Oncology November 2013 24(11):2911-2915

1083P KEYMAKER 02B: A randomized trial of pembrolizumab (pembro) alone or with investigational agents as first-line treatment for advanced melanoma

Authors: Dummer, R., Shapira, R., Pigozzo, J., Ascierto, P.A., Gaudy Marqueste, C., Portnoy, D., Del Vecchio, M., Bar-Sela, G., Cohen, J.E., Di Giacomo, A.M., Ribas, A., Dutriaux, C., Belli, C., Cohen, G., Dokhan, R., Jing, N., Lal, R., Krepler, C., Long, G.V.

Source: In Annals of Oncology September 2024 35 Supplement 2:S717-S718

1081MO Phase I study of WNT974 in combination with spartalizumab in patients with cutaneous melanoma

Authors: Ascierto, P.A., Rodon, J., De Vos, F.Y.F.L., Gambardella, V., De Miguel, M., Marquez-Rodas, I., Gil Martín, M., Robert, C., Del Vecchio, M., Moreno Garcia, V., Schadendorf, D., Jamal, R., Sloan, S., Mclaughlin, M., Murray, S., Gomez-Carrillo Ruiz, B., Hsiue, E., Moody, S., Arance, A.M.

Source: In Annals of Oncology September 2024 35 Supplement 2:S716-S717

1078MO Pembrolizumab (pembro) vs placebo as adjuvant therapy for high-risk stage II melanoma: Long-term follow-up, rechallenge, and crossover in KEYNOTE-716

Authors: Luke, J.J., Ascierto, P.A., Khattak, M.A., Rutkowski, P., Del Vecchio, M., Spagnolo, F., Mackiewicz, J., Cruz Merino, L. de la, Chiarion Sileni, V., Kirkwood, J.M., Robert, C., Schadendorf, D., De Galitiis, F., Carlino, M.S., Odeleye-Ajakaye, A., Kalabis, M., Krepler, C., Eggermont, A.M.M., Long, G.V.

Source: In Annals of Oncology September 2024 35 Supplement 2:S715-S715